What is the recommended continuous infusion rate for terlipressin?

Terlipressin Continuous Infusion Dosing

For continuous infusion of terlipressin in hepatorenal syndrome-acute kidney injury (HRS-AKI), start at 2 mg/day and titrate up to a maximum of 12 mg/day based on response, though evidence suggests 4 mg/day may be optimal for balancing efficacy and safety. 1, 2

Initial Dosing Strategy

• Start with 2 mg/day as a continuous intravenous infusion for the first 3 days of therapy 2, 3
• This lower starting dose for continuous infusion contrasts with the FDA-approved bolus regimen (1 mg every 6 hours = 4 mg/day) but has been shown to be equally effective with fewer adverse events 1, 2

Dose Titration Protocol

• Assess serum creatinine on Day 4 to determine if dose adjustment is needed 1, 4
• If serum creatinine decreases by ≥30% from baseline: Continue current infusion rate of 2 mg/day 2
• If serum creatinine decreases by <30% from baseline: Increase infusion rate progressively, up to a maximum of 12 mg/day 2, 3
• If serum creatinine is at or above baseline value: Discontinue terlipressin therapy 1, 4

Optimal Infusion Rate Based on Recent Evidence

• 4 mg/day continuous infusion appears to be the optimal dose based on recent research showing good efficacy with acceptable safety profile 5, 6
• A 2024 study of 136 patients demonstrated that 4 mg/day infusion achieved a 69.1% response rate with only 21.3% experiencing adverse events 5
• This dose is lower than the 8 mg/day mean dose often required with bolus administration, yet maintains comparable efficacy 2, 3

Duration of Therapy

• Continue infusion until 24 hours after two consecutive serum creatinine values ≤1.5 mg/dL (measured at least 2 hours apart) 1, 4
• Maximum treatment duration is 14 days 1, 4
• Mean treatment duration in clinical trials was 5-7 days 4, 5

Advantages of Continuous Infusion Over Bolus Dosing

The evidence strongly favors continuous infusion over intermittent bolus administration:

• Lower total daily dose required: Mean effective dose of 2.23 mg/day with infusion versus 3.51 mg/day with bolus (p<0.05) 2
• Fewer adverse events: 35.3% with infusion versus 62.2% with bolus (p<0.025) 2
• Better hemodynamic stability: Sustained effects on splanchnic circulation without the peaks and troughs of bolus dosing 5, 7
• Comparable or superior efficacy: 76.5% response rate with infusion versus 64.9% with bolus 2

Concomitant Albumin Administration

• Administer albumin 1 g/kg on Day 1 (maximum 100 g), followed by 20-40 g/day as clinically indicated 1, 4
• Reassess albumin need after 1-2 days based on volume status, as prolonged administration may contribute to respiratory complications 1
• Use point-of-care ultrasonography when available to guide volume management 1

Critical Safety Considerations

Contraindications to terlipressin infusion include: 1

• Oxygen saturation <90% on pulse oximetry
• Active coronary, peripheral, or mesenteric ischemia
• Known significant vascular disease
• Serum creatinine >5 mg/dL (unlikely to benefit)

Use with extreme caution in: 1

• ACLF Grade 3 (≥3 organ failures) - increased risk of respiratory failure
• MELD score ≥35
• Baseline hypoxemia or respiratory compromise
• Underlying cardiac dysfunction or cirrhotic cardiomyopathy

Monitoring Requirements

• Pulse oximetry monitoring every 2-4 hours is acceptable for patients with ACLF Grade <3, rather than continuous monitoring 1
• Monitor vital signs including blood pressure and heart rate regularly 1
• Daily serum creatinine to assess response 1, 4
• Watch for signs of ischemia (chest pain, abdominal pain, digital ischemia) 1

Administration Logistics

• Can be administered through a peripheral IV line - central line not required 1
• Does not require ICU-level monitoring for most patients (exception: ACLF Grade 3) 1
• Flush IV line after administration 4
• Stable in various diluents over 24-hour infusion periods 7

Common Pitfalls to Avoid

• Avoid excessive albumin administration, particularly in patients with baseline respiratory compromise or cardiac dysfunction, as this contributed to respiratory failure in the CONFIRM trial 1
• Do not continue therapy if serum creatinine fails to improve or worsens by Day 4 - this indicates non-response and increases risk without benefit 1, 4
• Do not use in patients with oxygen saturation <90% despite FDA approval, as respiratory failure risk is significantly elevated 1